HealthMore in Health→
Merck Eyes Lower Winrevair Dose for Rare Heart Failure Trial After Strong Early Signal
Key Takeaways
- Merck is planning a pivotal Winrevair trial in an uncommon heart-failure setting.
- The company is leaning toward a lower dose for Phase 3.
- The Phase 2 benefit at that dose was described as profound.
- Dose selection will be a critical determinant of the program’s late-stage prospects.
DE
DT Editorial Team··via endpoints.news